Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 794 participants.

Also called NCT02887183

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose other
Phase
Phase 4
Enrolled
  • 794 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02887183
Other papers using this trial's data
  • Comparative Effect of Angiotensin Receptor Neprilysin Inhibition on B-type Natriuretic Peptide Levels Measured by Three Different Assays: The PROVE-HF Study Clinical chemistry, 2022-11-03 DOI, PubMed 36103292
  • Dose-Response to Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction Journal of the American College of Cardiology, 2022-10-18 DOI, PubMed 36229089
  • Isovolumic Contraction Velocity in Heart Failure With Reduced Ejection Fraction and Effect of Sacubitril/Valsartan: the PROVE-HF Study Journal of cardiac failure, 2024-05 DOI, PubMed 37816446
  • Prediction of Left Ventricular Ejection Fraction Change Following Treatment With Sacubitril/Valsartan JACC. Heart failure, 2023-01 DOI, PubMed 36599549

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02887183. Allocation not applicable; no masking; primary purpose other. Start 2016-10-25 (actual); primary completion 2018-10-22 (actual). Results posted on 2019-12-05.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
Acronym
PROVE-HF
Condition
Heart Failure
Intervention (Drug)
LCZ696 (sacubitril/valsartan)
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct02887183
Content hash
866af7c8ecde0a3e2474582ea59e6c3795eb6f2be957b7542535f3c51aab83f8